What Strepsils Maxpro Treats: Main Uses and Benefits

Flurbiprofen lozenges are commonly used across conditions presenting with acute episodes of discomfort, primarily targeting the throat area. The medication is relevant for the symptomatic relief of pain, swelling, and inflammation associated with sore throats, and it is typically applied when supportive symptom management is appropriate.

The medication is specifically used in situations involving distressing symptoms such as moderate-to-severe throat pain, swelling, and related difficulty swallowing (dysphagia). It is applied when acute manifestations interfere with function, generally helping to address groups of symptoms that may become intense or disruptive. The intent is generally focused on easing the localized burden:

“The primary goal of this lozenge is to provide supportive relief that helps ease the overall symptom burden during a difficult episode.”

The medication is commonly used across conditions presenting with acute episodes, including pharyngitis and tonsillo-pharyngitis, where symptoms related to irritative states are pronounced.

Quick Fact: Relief for Acute Throat Symptoms
The lozenge is applied in contexts that involve acute symptom patterns, offering symptomatic support and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. Australian Therapeutic Goods Administration (TGA) product description

Official Eligibility Rules for Strepsils Maxpro

Regulatory documents establish strict eligibility criteria for the use of Strepsils Maxpro (Flurbiprofen lozenges), primarily based on age, patient history, and co-existing health conditions.

Approved and Restricted Populations

Classification	Population/Condition
Allowed Use	Adults and Adolescents aged 12 years and over are eligible under standard labeled conditions.
Not Recommended	Children under 12 years of age are not recommended due to insufficient safety and efficacy data.
Use with Caution	Older adults and patients with mild to moderate renal or hepatic impairment are restricted to use only with caution.

Contraindications (Absolute Prohibition)

Use of the medicine is contraindicated (must not be used) in patients with the following conditions:

• A history of hypersensitivity or allergic reactions to Flurbiprofen, Aspirin, or other NSAIDs.
• Active or recurrent peptic ulceration/hemorrhage or a history of gastrointestinal bleeding related to previous NSAID use.
• Severe heart failure, severe renal failure, or severe hepatic failure.
• Women in the third trimester of pregnancy (last three months).

Regulatory documents also state that use is not recommended for breastfeeding mothers.

Strepsils Maxpro contains the active ingredient Flurbiprofen, a Non-steroidal Anti-inflammatory Drug (NSAID). The interaction profile is defined by constraints common to the NSAID class, based strictly on official regulatory documentation.

Documented Pharmacological Interactions

Co-administration with other NSAIDs, including COX-2 selective inhibitors, is contraindicated due to an increased risk of adverse effects, such as gastrointestinal bleeding. The medicine is also restricted for a period of 8 to 12 days following the administration of Mifepristone to avoid interference with its therapeutic action.

Bleeding Risk: Flurbiprofen may enhance the effects of Anticoagulants (e.g., Warfarin) and increase the risk of bleeding when co-administered with Anti-platelet Agents or SSRIs. The risk of gastrointestinal adverse reactions is also increased with alcohol consumption.

Exposure Modification: Co-administration with certain drugs may elevate their serum concentrations. This applies to Lithium and Methotrexate, where caution is required if co-administered within 24 hours due to reduced clearance. Similarly, the levels of Cardiac Glycosides may increase. For patients identified as CYP2C9 poor metabolizers, a dose adjustment may be noted due to reduced metabolic clearance of Flurbiprofen itself.

Organ System Risk: Concomitant use with Antihypertensives (e.g., Diuretics, ACE inhibitors) may reduce their efficacy and increases the risk of nephrotoxicity. This risk is heightened in elderly or dehydrated patients.

The mechanism of action of Strepsils Maxpro is mediated by its active ingredient, Flurbiprofen, a non-steroidal anti-inflammatory compound. Its core function is the reversible inhibition of Cyclooxygenase ( COX) enzymes, specifically targeting both COX-1 and COX-2 isoforms.

This molecular interaction interrupts the Prostaglandin Synthesis Pathway by preventing the conversion of Arachidonic Acid into specific prostaglandins, such as Prostaglandin E2 ( PGE2). The resulting reduced local concentration of these inflammatory mediators modulates the chemical signaling cascade in the affected tissue.

This decrease in PGE2 concentration yields two simultaneous physiological actions. The reduced chemical signaling directly minimizes local vasodilation and plasma extravasation, which constitutes the anti-inflammatory physiological action. Additionally, removing the sensitizing PGE2 signal from peripheral nociceptors (pain-sensing nerves) modulates the nerve's threshold, which is the foundation of the analgesic physiological action.

How to Use Strepsils Maxpro: Official Administration Guidelines

Strepsils Maxpro, a formulation containing the active ingredient Flurbiprofen (8.75 mg), is intended for short-term, acute use. The medicine is designed exclusively for oro-mucosal administration, which involves dissolving the lozenge in the mouth to allow the active ingredient to act locally.

Official Dosing and Frequency

The standardized dosing regimen is intended for individuals aged 12 years and older.

Administration Parameter	Official Guideline
Single Dose	One lozenge (8.75 mg Flurbiprofen).
Dosing Interval	Repeat every three to six hours as required.
Maximum Daily Limit	A maximum of five lozenges in a 24 hour period.
Maximum Course Duration	Three days of continuous use.

---

Procedural Administration and Usage Constraints

The lozenge should be taken using the lowest effective dose for the shortest time necessary to manage symptoms. The administration process requires that the lozenge be sucked or dissolved slowly in the mouth to facilitate the intended oro-mucosal action. During the dissolution process, the lozenge must be moved around the mouth to avoid prolonged contact with a single area; this is a procedural requirement designed to limit localized irritation. The medicine is not intended for long-term management, and use beyond the three-day limit is not indicated.

Research evidence / Overview of studies

---

Key Findings on Efficacy and Duration

Research has examined this pharmaceutical agent as a potential treatment for mild to moderate pain and fever.

• Pain Relief: Studies investigated the agent's onset of action on pain, particularly for headaches and musculoskeletal aches. Its effect on pain duration was studied, including comparative investigations with other available options.
• Fever Reduction: Research examined whether it affected the intensity of common fever and headache. Evidence regarding its influence on core body temperature and patient-reported feeling of sickness was explored in clinical trials.
• Mechanism of Action: This section focuses on clinical trial outcomes and pharmacokinetics.

---

Pharmacokinetics and Administration

Studies have explored the body's processing of this compound:

• Absorption and Bioavailability: The combination was studied to determine if it altered the absorption of the active ingredient. Research examined the effect of dietary consumption on pharmacokinetic parameters, including the rate of absorption.
• Metabolism: The compound is primarily metabolized in the liver. Research on the pathways and speed of this metabolism was conducted.
• Elimination: The half-life, or the time it takes for half the substance to be eliminated from the body, has been documented in various study populations.

---

Safety and Tolerability Profile

Tolerability and the occurrence of adverse events in short-term use were investigated in multiple clinical trials.

• Reported Adverse Events: Reported adverse events in studies included nausea, stomach upset, and dizziness. The severity and duration of these events varied among participants.
• Liver Function: Research has investigated the pharmacokinetics and potential impact of the agent in study participants with liver disease. Studies have explored the impact of exceeding studied doses on liver enzymes and function.
• Kidney Function: Research has explored the effect of long-term use on kidney health, though most studies focused on short-term outcomes.

Key Studies & References

1. A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis (NCT01049334)
2. Flurbiprofen - LiverTox - NCBI Bookshelf (Safety/Liver Function)
3. A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions

Common questions about Strepsils Maxpro (FAQ)

---

Q: Is Strepsils Maxpro the same as regular Strepsils?

According to regulatory public information, the distinction between the products is based on the active ingredient. Strepsils Maxpro contains Flurbiprofen, which is classified as an NSAID (a medicine that relieves pain and inflammation). Standard Strepsils products typically use antiseptics like Amylmetacresol and Dichlorobenzyl Alcohol.

Q: Does Strepsils Maxpro help with cough or just sore throat?

Official regulatory documents indicate this medicine is for the symptomatic relief of sore throat, specifically by reducing associated pain and inflammation. The product's official uses do not list the relief of cough as an indicated treatment.

Q: Can Strepsils Maxpro be used by people with diabetes?

Official product information states that this lozenge contains liquid glucose and liquid sucrose as excipients (non-active ingredients). Based on this, official information suggests patients with diabetes review the product's excipients with a healthcare professional.

Q: How quickly does Strepsils Maxpro start to work after taking it?

Clinical studies examining the onset of action indicated that the median time to first perceived pain relief was approximately 11 minutes after administration. This finding indicates the active ingredient begins to provide pain relief within the first hour of administration.

Q: How long do the effects of one Strepsils Maxpro lozenge last?

Clinical trial data and official information indicate that the symptomatic relief provided by one lozenge may last for up to 6 hours.

Q: Does Strepsils Maxpro contain sugar?

Yes, the regulatory information confirms that Strepsils Maxpro contains both liquid glucose and liquid sucrose as excipients (non-active ingredients).

Q: Does using Strepsils Maxpro affect driving ability or focus?

Official safety sections state that no specific studies on the potential effects of the lozenge on the ability to drive and use heavy machinery have been conducted.

Q: Are there different strengths or flavors of Strepsils Maxpro available?

Regulatory product sheets specify that Strepsils Maxpro lozenges contain 8.75 mg of Flurbiprofen. The flavor listed in the official documents is Honey and Lemon.

Q: What is the purpose of the anesthetic component in Strepsils Maxpro?

The product’s only active ingredient is Flurbiprofen, which is classified as an NSAID (Non-Steroidal Anti-Inflammatory Drug) and an analgesic (pain reliever). The regulatory composition section does not list an anesthetic.

Q: Is Strepsils Maxpro safe for people with high blood pressure?

For individuals with pre-existing conditions such as high blood pressure (hypertension), regulatory documents state patients should review treatment with a healthcare professional. This is based on considerations related to the NSAID class of medicines.

Q: Can individuals with lactose intolerance use Strepsils Maxpro?

The regulatory-approved list of excipients (non-active ingredients) for Strepsils Maxpro does not list lactose.

Q: Is Strepsils Maxpro a prescription-only medicine?

This product is classified by various regulatory bodies as an Over-The-Counter (OTC) medicine. This means it is typically available for purchase without requiring a prescription.

Q: What should I do if my symptoms do not improve after using Strepsils Maxpro?

Official documents state that if symptoms persist, have not improved, or have worsened after the maximum recommended course of three days of use, medical consultation is indicated.

Q: What distinguishes Strepsils Maxpro from Strepsils Sore Throat & Blocked Nose?

The primary distinction lies in the active ingredients and therapeutic class. Strepsils Maxpro uses Flurbiprofen for its anti-inflammatory and analgesic action, while the Sore Throat & Blocked Nose variants use different active ingredients.

Q: Is the sensation of relief immediate after taking the lozenge?

Clinical studies examined the onset of action and found that the median time to first perceived pain relief was approximately 11 minutes after administration. Since the pain relief was measured at approximately 11 minutes following administration, the onset of relief is not instant.

Official Storage Conditions

To ensure the stability of the active ingredient, Flurbiprofen, Strepsils Maxpro lozenges must be stored under controlled conditions as defined by regulatory labeling:

• Temperature: Store the medicine at or below 30 C.
• Protection: The lozenges should be stored in the original package to protect the product from moisture.
• Prohibited Environments: Do not refrigerate or freeze the product.
• Child Safety: The product must be kept strictly out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Expired or unused Strepsils Maxpro must be handled responsibly, following established pharmaceutical waste rules:

• Prohibited Disposal: Medicines must not be thrown away via household waste or wastewater (such as flushing down a toilet or drain).
• Required Method: Any unused or expired product must be disposed of in accordance with local requirements, typically by returning it to a pharmacy or a designated collection program.